1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

30 Apr 2024
Admin
News Article

Glenmark Receives US FDA Approval for Acetaminophen and Ibuprofen Tablets

"Glenmark Pharma receives US FDA approval for acetaminophen and ibuprofen tablets, 250 mg/125 mg

Overview

Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led, global pharmaceutical company, has received final approval by the United States Food & Drug Administration (FDA) for acetaminophen and ibuprofen tablets, 250 mg/125 mg (OTC), determined by the FDA to be bioequivalent to Advil dual action with acetaminophen tablets, 250 mg/125 mg (OTC), of Haleon US Holdings, LLC.

Glenmark’s acetaminophen and ibuprofen tablets, 250 mg/125 mg (OTC), will be distributed in the US by Glenmark Therapeutics Inc., USA.

Annual Sales

According to Nielsen syndicated data for the latest 52 weeks period ending March 23, 2024, the Advil dual action with acetaminophen tablets, 250 mg/125 mg (OTC) market achieved annual sales of approximately $84.1 million.

Current Portfolio

Glenmark’s current portfolio consists of 195 products authorized for distribution in the US marketplace and 52 ANDA’s pending approval with the US FDA.
In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd. is a research-led, global pharmaceutical company, having a presence across branded, generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology.
The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!